PA
SDGR icon

PharVision Advisers’s Schrodinger SDGR Stock Holding History

PharVision Advisers’s Portfolio SDGR Stock Details SDGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,254
Closed -$286K – 970
2025
Q3 		$286K Buy
+14,254
New +$286K 0.16% 256

Other funds holding SDGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Gates Foundation Trust
Gates Foundation Trust Kirkland, Washington $34.4B AUM 26.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

PharVision Advisers's SDGR Position: Q4 2025 in Review

PharVision Advisers sold out of Schrodinger (SDGR) in Q4 2025, closing a stake of 14,254 shares — an estimated $286K sold.

PharVision Advisers first reported a position in SDGR in Q3 2025 and held it in 1 quarter. The position peaked at $286K in Q3 2025. 222 funds tracked by Wall St. Rank hold SDGR as of Q4 2025.

  • PharVision Advisers reported no remaining Schrodinger position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 14,254 Schrodinger shares in Q4 2025, an estimated $286K.
  • PharVision Advisers first reported a position in Schrodinger in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Schrodinger position peaked at $286K in Q3 2025.
  • 222 funds tracked by Wall St. Rank held Schrodinger as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.